ZA200808746B - New salts and crystalline salt forms of an indolinone derivative - Google Patents
New salts and crystalline salt forms of an indolinone derivativeInfo
- Publication number
- ZA200808746B ZA200808746B ZA200808746A ZA200808746A ZA200808746B ZA 200808746 B ZA200808746 B ZA 200808746B ZA 200808746 A ZA200808746 A ZA 200808746A ZA 200808746 A ZA200808746 A ZA 200808746A ZA 200808746 B ZA200808746 B ZA 200808746B
- Authority
- ZA
- South Africa
- Prior art keywords
- salt forms
- crystalline salt
- new salts
- indolinone derivative
- indolinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06115159A EP1870400A1 (en) | 2006-06-08 | 2006-06-08 | Salts and crystalline salt forms of an 2-indolinone derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200808746B true ZA200808746B (en) | 2009-05-27 |
Family
ID=37231603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200808746A ZA200808746B (en) | 2006-06-08 | 2008-10-14 | New salts and crystalline salt forms of an indolinone derivative |
Country Status (13)
Country | Link |
---|---|
US (1) | US20090318471A1 (xx) |
EP (7) | EP1870400A1 (xx) |
JP (1) | JP2009539798A (xx) |
KR (1) | KR20090026334A (xx) |
CN (1) | CN101466675A (xx) |
AU (1) | AU2007255393A1 (xx) |
BR (1) | BRPI0711956A2 (xx) |
CA (1) | CA2653527A1 (xx) |
IL (1) | IL195679A0 (xx) |
MX (1) | MX2008015646A (xx) |
RU (1) | RU2008151506A (xx) |
WO (1) | WO2007141283A2 (xx) |
ZA (1) | ZA200808746B (xx) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57035B1 (sr) | 2008-06-06 | 2018-05-31 | Boehringer Ingelheim Int | Farmaceutska kombinacija |
TW201011002A (en) * | 2008-07-29 | 2010-03-16 | Boehringer Ingelheim Int | New compounds |
JP2012515184A (ja) | 2009-01-14 | 2012-07-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大腸がんの治療方法 |
US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
EP2429520A1 (en) | 2009-05-14 | 2012-03-21 | Boehringer Ingelheim International GmbH | New combination therapy in treatment of oncological and fibrotic diseases |
US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
WO2012068441A2 (en) | 2010-11-19 | 2012-05-24 | Ratiopharm Gmbh | Intedanib salts and solid state forms thereof |
US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
CN104003925B (zh) * | 2013-06-05 | 2016-03-30 | 四川大学 | 吲哚酮化合物或其衍生物及其用途 |
AU2014296032A1 (en) | 2013-07-31 | 2016-03-17 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
CN106008308A (zh) * | 2015-03-13 | 2016-10-12 | 正大天晴药业集团股份有限公司 | 尼达尼布乙磺酸盐结晶 |
WO2017142002A1 (ja) * | 2016-02-17 | 2017-08-24 | 大正製薬株式会社 | C-4"位置換マクロライド化合物フリー体及び塩の結晶形並びにそれらの製造方法 |
CZ2016104A3 (cs) | 2016-02-24 | 2017-09-06 | Zentiva, K.S. | Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy |
US20190160054A1 (en) | 2016-04-13 | 2019-05-30 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer |
EP3246029A1 (en) | 2016-05-19 | 2017-11-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer |
EP3464240A1 (en) | 2016-05-27 | 2019-04-10 | Boehringer Ingelheim International GmbH | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
JP2019523225A (ja) | 2016-06-01 | 2019-08-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ニンテダニブおよびピルフェニドンによる治療開始を決定するためのecmバイオマーカーの使用 |
EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
TWI632133B (zh) * | 2017-03-15 | 2018-08-11 | 新源生物科技股份有限公司 | 3-z-[1-(4-(n-((4-甲基-哌嗪-1-基)-甲羰基)-n-甲基-胺基)-苯胺基)-1-苯基-亞甲基]-6-甲氧羰基-2-吲哚啉酮的晶型 |
CN110573161A (zh) | 2017-03-28 | 2019-12-13 | 勃林格殷格翰国际有限公司 | 用于治疗肌营养不良的方法的尼达尼布 |
MX2020004173A (es) | 2017-10-23 | 2020-08-03 | Boehringer Ingelheim Int | Nueva combinacion de agentes activos para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas (pf-ild). |
CN109758437A (zh) * | 2017-11-09 | 2019-05-17 | 北京盈科瑞创新药物研究有限公司 | 一种雾化吸入用尼达尼布冻干脂质体制剂及其制备方法 |
CN111465594B (zh) | 2017-11-17 | 2023-11-07 | 费米有限公司 | 已知作为制备尼达尼布中间体的2-吲哚满酮的合成 |
BR112020018064A2 (pt) | 2018-03-07 | 2020-12-22 | Pliant Therapeutics, Inc. | Compostos de aminoácidos e métodos de uso |
WO2020041631A1 (en) * | 2018-08-22 | 2020-02-27 | Avalyn Pharma Inc. | Specially formulated compositions of inhaled nintedanib and nintedanib salts |
TW202210480A (zh) * | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
US20230135671A1 (en) | 2020-04-01 | 2023-05-04 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
-
2006
- 2006-06-08 EP EP06115159A patent/EP1870400A1/en not_active Withdrawn
-
2007
- 2007-06-06 CN CNA2007800211566A patent/CN101466675A/zh active Pending
- 2007-06-06 US US12/303,278 patent/US20090318471A1/en not_active Abandoned
- 2007-06-06 MX MX2008015646A patent/MX2008015646A/es not_active Application Discontinuation
- 2007-06-06 KR KR1020097000328A patent/KR20090026334A/ko not_active Application Discontinuation
- 2007-06-06 EP EP11158873A patent/EP2366689A1/en not_active Withdrawn
- 2007-06-06 AU AU2007255393A patent/AU2007255393A1/en not_active Abandoned
- 2007-06-06 WO PCT/EP2007/055541 patent/WO2007141283A2/en active Application Filing
- 2007-06-06 EP EP07729916A patent/EP2029533A2/en not_active Ceased
- 2007-06-06 RU RU2008151506/04A patent/RU2008151506A/ru unknown
- 2007-06-06 EP EP11158869A patent/EP2366688A1/en not_active Withdrawn
- 2007-06-06 CA CA002653527A patent/CA2653527A1/en not_active Abandoned
- 2007-06-06 JP JP2009513684A patent/JP2009539798A/ja active Pending
- 2007-06-06 EP EP11158863A patent/EP2364968A1/en not_active Withdrawn
- 2007-06-06 BR BRPI0711956-9A patent/BRPI0711956A2/pt not_active IP Right Cessation
- 2007-06-06 EP EP11158877A patent/EP2366690A1/en not_active Withdrawn
- 2007-06-06 EP EP11158866A patent/EP2364969A1/en not_active Withdrawn
-
2008
- 2008-10-14 ZA ZA200808746A patent/ZA200808746B/xx unknown
- 2008-12-03 IL IL195679A patent/IL195679A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20090026334A (ko) | 2009-03-12 |
EP2366688A1 (en) | 2011-09-21 |
EP2366689A1 (en) | 2011-09-21 |
EP1870400A1 (en) | 2007-12-26 |
CN101466675A (zh) | 2009-06-24 |
US20090318471A1 (en) | 2009-12-24 |
RU2008151506A (ru) | 2010-07-20 |
WO2007141283A2 (en) | 2007-12-13 |
WO2007141283A3 (en) | 2008-03-06 |
AU2007255393A1 (en) | 2007-12-13 |
MX2008015646A (es) | 2009-01-12 |
BRPI0711956A2 (pt) | 2012-01-17 |
JP2009539798A (ja) | 2009-11-19 |
IL195679A0 (en) | 2009-09-01 |
CA2653527A1 (en) | 2007-12-13 |
EP2364969A1 (en) | 2011-09-14 |
EP2029533A2 (en) | 2009-03-04 |
EP2366690A1 (en) | 2011-09-21 |
EP2364968A1 (en) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200808746B (en) | New salts and crystalline salt forms of an indolinone derivative | |
HK1200440A1 (zh) | 種抑制劑的結晶形式 | |
PL2134685T3 (pl) | Pochodne indolu niepodstawione w pozycji 7 jako inhibitory Mcl-1 | |
EP2049124A4 (en) | PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER | |
EP2170076A4 (en) | 4-CARBOXYBENZYLAMINO DERIVATIVES AS HISTONDEACETYLASE INHIBITORS | |
IL193422A0 (en) | Amide derivative or salt thereof | |
IL192603A0 (en) | Thieno-pyridine derivatives as mek inhibitors | |
HK1145148A1 (en) | Solvate and crystalline forms of carbamoyl-cyclohexane derivatives | |
IL194478A0 (en) | Salt of sulfinylbenzimidazole compound, and crystal and amorphous form thereof | |
EP2038282A4 (en) | SALTS OF PYRROLOPYRIMIDINONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | |
IL198264A0 (en) | Crystalline modification of fipronil | |
SI2303866T1 (sl) | Kristalne oblike natrijevega rabeprazolata | |
IL198265A (en) | Crystalline change of fibronyl | |
HK1125376A1 (en) | Salt of cd 80 antagonist cd80 | |
EP2121727A4 (en) | CRYSTALLINE FORMS OF THE MONOSODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHANE | |
ZA200806725B (en) | New citrate salt of an indole derivative and its pharmaceutical use | |
IL195061A0 (en) | Crystalline forms of atorvastatin | |
EP2042499A4 (en) | SALTS OF MORPHOLINE COMPOUND | |
HRP20160616T1 (hr) | Soli perindoprila | |
ZA200706292B (en) | Novel salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives | |
EP2017254A4 (en) | CRYSTALLIZATION PROCESS | |
AP2717A (en) | Mono-hydrochloric salts of an inhibitor of histonedeacetylase | |
PL383821A1 (pl) | Nowa postać polimorficzna krystalicznej półwapniowej soli atorwastatyny | |
ZA201101583B (en) | Novel salt of morpholine derivative | |
PL386948A1 (pl) | Sposób otrzymywania amorficznej soli sodowej fluwastatyny |